Design, synthesis, and biological evaluation of caprolactam-modified bengamide analogues

ChemMedChem. 2008 Jan;3(1):74-8. doi: 10.1002/cmdc.200700214.

Authors

Gang Liu¹, Yi-Ming Ma, Wan-Yi Tai, Chuan-Ming Xie, Yu-Lin Li, Jia Li, Fa-Jun Nan

Affiliation

¹ Chinese National Center for Drug Screening, Shanghai Institute of Materia Medica, 189 Guo Shou Jing Road, Shanghai 201203, China.

PMID: 17994598
DOI: 10.1002/cmdc.200700214

No abstract available

Publication types

Evaluation Study
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / chemical synthesis
Antineoplastic Agents / pharmacology*
Azepines
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Caprolactam / chemical synthesis
Caprolactam / pharmacology*
Drug Design*
Humans
Inhibitory Concentration 50
Solubility
Structure-Activity Relationship
Tumor Cells, Cultured / drug effects
Tumor Cells, Cultured / pathology
Water / chemistry

Substances

3,4,5-trihydroxy-2--methoxy-8,8-dimethyl-N-(hexahydro-2-oxo-6-(cyclohexylcarbonyl)oxy-2H-azepin-3-yl)non-6-enamide
Antineoplastic Agents
Azepines
Water
bengamide B
Caprolactam